Identification of distinct mutations, such as those in EGFR observed in lung adenocarcinoma, and of their correlation with heightened bone metastasis presents precise targets for therapeutic measures and prognostic evaluations. This evidence concerns the gene EGFR and lung adenocarcinoma.